- Pulmonx press release ( NASDAQ: LUNG ): Q4 GAAP EPS of -$0.38 beats by $0.04 .
- Revenue of $15.43M (+12.6% Y/Y) beats by $1.45M .
- Added 17 new U.S. treatment centers for Zephyr Valves in the fourth quarter 2022, increasing total U.S. treatment centers to 278
-
Pulmonx expects revenue for the full year 2023 to be in the range of $63 million to $65 million vs. $62.1M consensus
The Company expects gross margin for the full year 2023 to fall within the range of 73% to 74%.
Pulmonx expects total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.
For further details see:
Pulmonx GAAP EPS of -$0.38 beats by $0.04, revenue of $15.43M beats by $1.45M